US 12,441,804 B2
Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
Akihisa Kaneko, Shizuoka (JP); Yuki Iwayanagi, Shizuoka (JP); Hidetomo Kitamura, Shizuoka (JP); Yoshinobu Higuchi, Shizuoka (JP); Hiroaki Matsushita, Shizuoka (JP); Ryosuke Mihara, Tokyo (JP); Yumi Yamamoto, Tokyo (JP); Tomohisa Saito, Tokyo (JP); and Keiko Hirokawa, Tokyo (JP)
Assigned to Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
Filed by Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
Filed on Aug. 8, 2023, as Appl. No. 18/366,770.
Application 18/366,770 is a continuation of application No. 16/713,271, filed on Dec. 13, 2019, granted, now 11,773,173.
Application 16/713,271 is a continuation of application No. 15/563,743, granted, now 10,544,227, issued on Jan. 28, 2020, previously published as PCT/JP2016/061859, filed on Apr. 13, 2016.
Claims priority of application No. 2015-082699 (JP), filed on Apr. 14, 2015; and application No. 2016-041641 (JP), filed on Mar. 4, 2016.
Prior Publication US 2024/0018249 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2866 (2013.01) [A61K 39/395 (2013.01); A61K 39/39541 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); C07K 16/24 (2013.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01)] 16 Claims
 
1. A method of treating, or reducing the incidence of, a symptom of IL-31-induced pruritis or sleep disturbance in a human patient, the method comprising subcutaneously administering to the patient a series of doses of an anti-humanIL-31RA antibody,
wherein the antibody comprises an H chain variable region comprising CDR1 as set forth in SEQ ID NO: 1, CDR2 as set forth in SEQ ID NO: 2, and CDR3 as set forth in SEQ ID NO: 3, and an L chain variable region comprising CDR1 as set forth in SEQ ID NO: 4, CDR2 as set forth in SEQ ID NO: 5, and CDR3 as set forth in SEQ ID NO: 6,
wherein the patient is a child younger than 18 years,
wherein the amount of the antibody in each individual dose in the series is within the range of 5 mg/body to 15 mg/body, and
wherein the interval between each administration and the next is 4 weeks.